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wiOBJECTIVES The study sought to examine prognostic relevance of T1 mapping parameters (based on a T1 mapping
method) in nonischemic dilated cardiomyopathy (NIDCM) and compare them with conventional markers of adverse
outcome.
BACKGROUND NIDCM is a recognized cause of poor clinical outcome. NIDCM is characterized by intrinsic myocardial
remodeling due to complex pathophysiological processes affecting myocardium diffusely. Lack of accurate and nonin-
vasive characterization of diffuse myocardial disease limits recognition of early cardiomyopathy and effective clinical
management in NIDCM. Cardiac magnetic resonance (CMR) supports detection of diffuse myocardial disease by T1
mapping.
METHODS This is a prospective observational multicenter longitudinal study in 637 consecutive patients with dilated
NIDCM (mean age 50 years [interquartile range: 37 to 76 years]; 395 males [62%]) undergoing CMR with T1 mapping and
late gadolinium enhancement (LGE) at 1.5-T and 3.0-T. The primary endpoint was all-cause mortality. A composite of
heart failure (HF) mortality and hospitalization was a secondary endpoint.
RESULTS During a median follow-up period of 22 months (interquartile range: 19 to 25 months), we observed a total of
28 deaths (22 cardiac) and 68 composite HF events. T1 mapping indices (native T1 and extracellular volume fraction), as
well as the presence and extent of LGE, were predictive of all-cause mortality and HF endpoint (p < 0.001 for all). In
multivariable analyses, native T1 was the sole independent predictor of all-cause and HF composite endpoints (hazard
ratio: 1.1; 95% conﬁdence interval: 1.06 to 1.15; hazard ratio: 1.1; 95% conﬁdence interval: 1.05 to 1.1; p < 0.001 for
both), followed by the models including the extent of LGE and right ventricular ejection fraction, respectively.
CONCLUSIONS Noninvasive measures of diffuse myocardial disease by T1 mapping are signiﬁcantly predictive
of all-cause mortality and HF events in NIDCM. We provide a basis for a novel algorithm of risk stratiﬁcation
in NIDCM using a complementary assessment of diffuse and regional disease by T1 mapping and LGE,
respectively. (J Am Coll Cardiol Img 2016;9:40–50) © 2016 by the American College of Cardiology Foundation.m the *Guys and St Thomas’ NHS Trust, London, England; yKing’s College Hospital NHS Trust, London, England; zDepartment
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AB BR E V I A T I O N S
AND ACRONYM S
CMR = cardiac magnetic
resonance
ECV = extracellular volume
fraction
EF = ejection fraction
HF = heart failure
IQR = interquartile range
LGE = late gadolinium
enhancement
LV = left ventricular
NIDCM = nonischemic dilated
cardiomyopathy
NYHA = New York Heart
Association
RV = right ventricular
SAX = short axis
standard deviation
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41N onischemic dilated cardiomyopathy(NIDCM) is an increasingly recognized causeof cardiovascular morbidity and mortality
(1–3). In NIDCM, a number of diverse inﬂuences pro-
mote intrinsic myocardial impairment and remodel-
ing via complex pathophysiological processes
including extracellular matrix remodeling, myoﬁbro-
blast transformation, and cardiomyocyte cell loss,
affecting the myocardium diffusely (4,5). The lack
of accurate and noninvasive characterization of
diffuse myocardial disease limits its early recogni-
tion and effective clinical management. Endomyo-
cardial biopsy is the suggested gold standard for
detection and classiﬁcation of myocardial tissue ab-
normalities, yet its invasiveness, low diagnostic
yield, and paucity of proven consequential manage-
ment pathways limit its widespread use in guiding
clinical management (6). Cardiac magnetic resonance
(CMR) is able to visualize regional myocardial disease
by late gadolinium enhancement (LGE) and has gained
relevance in clinical management of cardiomyopa-
thies by informing on the underlying etiology and sup-
porting risk stratiﬁcation in NIDCM (7,8). Because LGE
relies on regional differences in tissue composition, it
is an imperfect measure of diffuse interstitial disease
underlying myocardial impairment in NIDCMs (9,10).
Myocardial T1 mapping is emerging as the noninvasive
method of choice in assessment of diffuse myocardial
disease allowing quantiﬁcation of altered magnetiza-
tion properties, which relate to the pathophysiological
changes in the myocardium. Studies have shown that
T1 mapping measurements correlate with extracel-
lular collagen volume fraction (9,11–14), are raised
in a number of NIDCMs and relate to the severity of
left ventricular (LV) remodeling in NIDCM (9–11,15).
The relationship with outcome of these novel parame-
ters in NIDCM and their comparative value against
conventional markers of adverse outcome remain
unknown.SEE PAGE 51METHODS
STUDY DESIGN. This is a prospective longitudinal
observational multicenter investigator-led study ofreceived funding from the German Ministry of Education and Research v
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Manuscript received October 28, 2015; revised manuscript received Decembthe prognostic value of noninvasive T1 map-
ping measures in a cohort of adult patients
with NIDCM. The multicenter consortium has
been described previously (16). Standardiza-
tion of T1 mapping acquisition was performed
at all participating centers prior to the onset of
patient recruitment. Participating centers
support large CMR clinical service (>1,000
patients a year) and provide clinical care
compliant with international guidelines and
recommendations on patient management.
The study protocol was reviewed and ap-
proved by the respective institutional ethics
committees and written informed consent
was obtained from all participants. All pro-
cedures were carried out in accordance with
the Declaration of Helsinki (2000).
Consecutive subjects (n ¼ 713) fulﬁlling the
accepted diagnostic criteria for NIDCM (1–3)
were enrolled between January 2011 and July 2014.
Prior to enrolment, the diagnosis was conﬁrmed by
CMR on the basis of increased LV end-diastolic volume
indexed to body surface area and reduced LV ejection
fraction (EF) compared with published reference
ranges normalized for age and sex (7). Patients
were excluded (based on previous medical history,
other investigations or CMR ﬁndings) if they had
evidence of: 1) ischemic heart disease, deﬁned as sig-
niﬁcant documented coronary artery disease, previous
coronary revascularization, previous history of
myocardial infarction, or evidence of ischemic type
LGE, or inducible ischemia on stress testing (17);
2) myocardial inﬁltration due to amyloidosis, iron
accumulation, lipid-storage disease, hypertrophic or
arrhythmogenic right ventricular (RV) cardiomyopa-
thy (1–3), or myocardial inﬂammation (18); or 3) sig-
niﬁcant primary valvular heart disease (1–3).
Additional exclusion criteria were the gen-
erally accepted contraindications to CMR (implan-
table devices, cerebral aneurysm clips, cochlear
implants, severe claustrophobia), history of renal dis-
ease with a current estimated glomerular ﬁltration
rate<30 ml/min/1.73 m2, unable to receive gadolinium
contrast agent, and inability to provide informed
consent. Clinical metadata were collected for all
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TABLE 1 Patients’ Baseline Characteristics: Demographic Data
All Patients
(N ¼ 637)
Survived
(n ¼ 609)
Died
(n ¼ 28) p Value
Age, yrs 50 (37–76) 49 (36–76) 50 (43–74) 0.60
Male 395 (62) 375 (61) 20 (71) 0.29
BMI, kg/m2 27 (23–30) 27 (23–31) 26 (20–29) 0.34
Heart rate, beats/min 69 (60–79) 70 (60–77) 69 (57–75) 0.99
Systolic blood pressure, mm Hg 127 (113–139) 126 (113–138) 128 (106–141) 0.54
Diastolic blood pressure, mm Hg 79 (71–85) 79 (68–84) 80 (71–88) 0.26
eGFR, ml/min/1.73 m2 79 (76–81) 78 (77–82) 76 (58–79) 0.11
Hematocrit, % 43 (39–46) 44 (39–46) 42 (36–45) 0.21
Hypertension 306 (48) 291 (48) 15 (54) 0.54
Diabetes 153 (24) 146 (24) 7 (24) 0.99
Atrial ﬁbrillation 54 (8) 53 (9) 2 (7) 0.72
High cholesterol 191 (30) 183 (30) 8 (28) 0.82
Smoking, current or previous 178 (28) 169 (28) 9 (32) 0.65
Family history of cardiomyopathy
or SCD
57 (9) 56 (9) 1 (0.4) 0.11
Alcohol excess 73 (13) 72 (13) 1 (0.4) 0.05
Chronic kidney impairment 102 (16) 96 (16) 6 (21) 0.48
NYHA functional class
#II 452 (71) 438 (72) 15 (53) 0.03
>III 185 (29) 171 (28) 13 (46) 0.04
MAGGIC score 13 (10–19) 13 (10–19) 14 (11–18) 0.12
Medication
RAS inhibitors 370 (58) 359 (59) 11 (39) 0.04
Diuretics 242 (38) 233 (39) 9 (32) 0.45
Beta-blockers 178 (29) 170 (28) 8 (29) 0.91
Calcium-channel blockers 172 (27) 167 (27) 5 (19) 0.34
Values are median (interquartile range) or n (%). Comparison between groups was made between patients
that survived and died. Signiﬁcance relates to the comparisons between patients that survived and died
(p < 0.05 is considered signiﬁcant). Values in bold indicate signiﬁcance. Hematocrit was obtained by means of
routine blood tests.
BMI ¼ body mass index; eGFR ¼ estimated glomerular ﬁltration rate; NYHA ¼ New York Heart Association;
RAS ¼ renin-angiotensin-aldosterone system; SCD ¼ sudden cardiac death.
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42subjects, as summarized in Tables 1 and 2. MAGGIC
integer score was used to approximate the pretest
likelihood of mortality due to heart failure (HF) in the
present cohort (19).
STUDY PROCEDURES. All subjects underwent a
standardized CMR protocol for routine assessment of
cardiac volumes, mass, and LGE, at 1.5-T or 3.0-T
Philips scanners (details of acquisition and post-
processing available in the Online Appendix) (20).
Modiﬁed Look-Locker imaging ((3(3)3(3)5)) was
employed for T1 mapping and performed in a single
midventricular short-axis (SAX) slice at mid-diastole,
prior to and w15 min after administration of gadobu-
trol (Gadovist, Bayer, Leverkusen, Germany) (Figure 1)
(10,13,15,16). The details of sequence parameters
are provided in the Online Appendix. LV and RV vol-
umes and function and the presence of LGE were
interpreted locally, following standardized recom-
mendations, to guide subsequent management
decisions (17). Quantitative analysis of LGE extent andT1 mapping was performed centrally and not used in
clinical management. LGE was quantiﬁed by a semi-
automatic detection method using a previously vali-
dated method of full-width at half maximum and
reported as a percentage of total LV mass (7,8,20). The
distribution of LGE was characterized as midwall,
epicardial, focal/involving the RV insertion points, or
diffuse, based on the predominant pattern (7,8,17).
Recovery rate of T1 relaxation was measured in a
midventricular SAX slice conservatively within the
septal myocardium (septal) as well as in the whole SAX
myocardium, as previously described and validated
(10,13,15,16,21). Extracellular volume fraction (ECV), a
marker of interstitial contrast agent accumulation was
calculated using T1 measurements of septal myocar-
dium and blood pool pre- and post-contrast, and
hematocrit value (22). Hematocrit was derived from
routine bloods nearest to the CMR examination.
Follow-up was performed by review of electronic
databases and telephone interviews after a minimum
of 6 months. Medical records were examined for
details on clinical presentation, entries of outpatient
visits, hospitalizations, and medical procedures.
A total of 53 patients (8%), lost to follow-up due to
relocation (n ¼ 37) or loss of contact (n ¼ 16), and a
further 23 with nondiagnostic images (signiﬁcant
breathing motion, mistriggering due to arrhythmia)
were not included in the ﬁnal analysis.
The predeﬁned primary endpoint was death from
any cause (all-cause mortality). Secondary endpoint
was a HF composite endpoint (HF death or unplanned
HF hospitalization) whereby the ﬁrst single event per
patient was included in the analysis (23). Primary
endpoint events were adjudicated by a committee of
independent physicians, blinded to the imaging
results. Cause of death was established from a com-
bination of death certiﬁcation, available postmortem
data, patients’ physicians, and review of medical
records for patients who died while hospitalized.
Mode of death was classiﬁed according to a modiﬁed
Hinkle-Thaler system (7). Sudden cardiac death was
deﬁned as unexpected death either within 1 h of
cardiac symptoms in the absence of progressive car-
diac deterioration, during sleep, or within 24 h of last
being seen alive. HF death was deﬁned as death
associated with unstable, progressive deterioration of
pump function despite active therapy. Aborted sud-
den cardiac death was diagnosed in patients who
received an appropriate implantable cardioverter-
deﬁbrillator shock for ventricular arrhythmia, or had
a documented nonfatal episode of ventricular ﬁbril-
lation or spontaneous sustained ventricular tachy-
cardia (>30 s in duration) causing hemodynamic
compromise and requiring cardioversion. HF
TABLE 2 Patients’ Baseline Characteristics: CMR Findings
All Patients
(N ¼ 637)
Survived
(n ¼ 609)
Died
(n ¼ 28) p Value
CMR quantiﬁcation of
function and
structure
LVEDV index, ml/m2 109 (89–132) 106 (91–123) 119 (89–129) 0.04
LVESV index, ml/m2 48 (31–58) 48 (32–53) 59 (44–72) 0.07
LVEF, % 47 (29–50) 48 (45–51) 43 (35–49) 0.11
LV mass index, g/m2 88 (62–98) 88 (62–97) 97 (64–114) 0.03
RVEF, % 53 (31–61) 54 (47–61) 42 (33–56) <0.01
CMR tissue characterization
LGE (present) 171 (27) 157 (26) 14 (50) 0.005
LGE type
Midwall stria 70 (11) 60 (10) 10 (36) 0.004
Epicardial 26 (4) 23 (4) 3 (11) 0.08
Regional ﬁbrosis
(patchy)
32 (5) 30 (5) 2 (7) 0.64
Diffuse 43 (7) 41 (8) 3 (11) 0.57
LGE extent
(% of LV volume)
6.2 (2.1–9.5) 4.1 (2.1–9.2) 9.9 (6.7–13.4) <0.01
CMR T1 mapping
1.5-T (n ¼ 357)
Native T1 (septal), ms 997 (958–1056) 994 (957–1020) 1069 (1036–1103) <0.001
Native T1 (SAX), ms 962 (842–1031) 951 (842–1019) 999 (903–1036) 0.01
Post-contrast T1, ms 439 (397–483) 439 (396–489) 435 (401–498) 0.58
ECV, % 26 (21–32) 26 (21–31) 30 (24–36) 0.03
3.0-T (n ¼ 280)
Native T1, ms 1113 (1064–1157) 1110 (1059–1152) 1183 (1126–1211) <0.001
Native T1 (SAX), ms 1058 (958–1128) 1056 (962–1121) 1094 (983–1172) 0.02
Post-contrast T1, ms 441 (401–489) 437 (401–489) 424 (403–489) 0.36
ECV, % 26 (21–32) 26 (21–30) 31 (26–35) 0.02
Values are median (interquartile range) or n (%). Values in bold indicate signiﬁcance.
CMR ¼ cardiac magnetic resonance; ECV ¼ extracellular volume fraction; EF ¼ ejection fraction; LGE ¼ late
gadolinium enhancement; LV ¼ left ventricular; LVEDV ¼ left ventricular end-diastolic volume; LVESV ¼ left
ventricular end-systolic volume; RVEDV ¼ right ventricular end-diastolic volume; SAX ¼ short axis.
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43hospitalization was categorized in patients admitted
to the hospital with signs and symptoms of decom-
pensated HF requiring treatment with an intravenous
HF medication (diuretics, vasodilators, or inotropic
agents).
STATISTICAL ANALYSIS. Statistical analysis was
performed using SPSS version 22 (IBM, Chicago,
Illinois; details in the Online Appendix). All tests were
2-tailed and a p value of <0.05 was statistically
signiﬁcant. Baseline subject characteristics (Tables 1
and 2), grouped by the dichotomous primary
endpoint, are presented as frequency (percentage) for
categorical data and median (interquartile range
[IQR]) for continuous data. Time to event was
measured from the date of CMR study. Missing data
for hematocrit were solved using recommended ap-
proaches (24). Univariate Cox proportional hazards
models were used to test the association between the
endpoints and baseline covariates (unadjusted haz-
ard ratio and 95% conﬁdence interval). Multivariable
analysis was performed with a forward selection
(likelihood ratio) modeling to determine independent
associations with outcome (adjusted hazard ratio and
95% conﬁdence interval), accounting for the rule of
thumb for logistic and Cox models with a minimum of
10 outcome events per predictor variable (3 for all-
cause mortality, 6 for HF endpoint), as well as inter-
relatedness of variables, using the best-of-the-group
approach (further details in the Online Appendix).
We transformed the T1 mapping variables into
categorical variables using: 1) the cutoff values as 2
standard deviations (SD) above the mean of the
reference range (identiﬁcation of abnormal myocar-
dium), as well as ranking by 2n-times SD of the
normal range (see the Online Appendix for details)
(16); and 2) the classiﬁcation into lower-to-middle
versus upper tertile (patients with high risk of
events).
Comparative performance of clinical decision-
making (classiﬁcation of subjects and events)
against clinical standards based on LVEF <35% and
LGE (25,26) were assessed using multivariate Cox
regression.
RESULTS
STUDY POPULATION. Patient characteristics are
summarized in Tables 1 and 2. A total of 637 subjects
(mean age 50 years [IQR: 37 to 76 years]; 395 [62%]
males) were included in the ﬁnal analysis. The most
common lead symptom included dyspnea (45%) and
atypical chest discomfort (30%). Sixty-two patients
(7%) presented with malignant ventricular arrhyth-
mias. Seventy-four patients received an implantablecardioverter-deﬁbrillator during the time of the
follow-up. At the time of the CMR study, 71% of pa-
tients were New York Heart Association (NYHA)
functional class II or less, and a total of 408 (64%) of
subjects were taking regular cardiac medications.
Hematocrit was available in 84.1% of subject and
obtained on the same day in 49% (n ¼ 312; overall
mean time interval 8  21 days, maximum 41 days).
Subjects previously diagnosed with chronic kidney
disease (n ¼ 102) received a reduced dose of gado-
butrol (0.01 mmol).
ENDPOINTS. During a median follow-up of 22
months (IQR: 7 months) we observed a total of 28
deaths (cumulative event rate 4.4%). Cardiac mor-
tality (n ¼ 22, 3.5%) was the principal cause of the
overall mortality. Patients who died were more likely
to have evidence of adverse LV remodeling (Table 2),
as well as raised T1 mapping indices, as well as
presence and extent of LGE. HF endpoint consisted of
68 events (10.7%) due to HF death (n ¼ 8), and
FIGURE 1 Diffuse and Regional Myocardial Disease by T1 Mapping and LGE,
Respectively
Representative images of T1 mapping, evaluation of diffuse myocardial disease by native
and post-contrast (not shown) acquisition with (A) septal and (B) short-axis sampling, and
(C) late gadolinium enhancement (LGE) (regional myocardial disease). Arrow points to
midventricular stria. CMR ¼ cardiac magnetic resonance.
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44unanticipated HF hospitalizations (n ¼ 60). Whereas
no patient underwent cardiac transplantation, 2
subjects were referred for LV assist device, but not
implanted within the follow-up period. The median
MAGGIC integer score was similar between the pa-
tients who survived and died, however, the score was
higher in subjects who sustained a composite HF
endpoint (median no event vs. event: 13 [IQR: 10 to
18] vs. 15 [IQR: 11 to 22]; p ¼ 0.003).PREDICTIVE ASSOCIATIONS. In univariate Cox
regression analyses, native T1 (septal and SAX), ECV,
the presence and extent of LGE, and RVEF showed
signiﬁcant predictive associations with all-cause
mortality and HF endpoint (p < 0.001) (Tables 3 and 4,
Figures 2 and 3). LV end-diastolic volume, LVEF, and
LV mass were less strongly associated with survival
(p < 0.05). NYHA functional class >II and MAGGIC
score were not associated with all-cause mortality;
however, there was a relationship with the HF
endpoint (p < 0.01). Other patient characteristics had
no signiﬁcant relationship with outcome. In multi-
variate stepwise analyses, native T1(septal) was the
sole independent predictor of outcome, followed by
themodelswith native T1(septal) and the extent of LGE
for all-causemortality, and native T1(septal) and RVEF
for HF endpoint, respectively (Tables 3 and 4).
Dichotomized variables, native T12SD (normal/
abnormal) (16), and native T14SD and native T1tertiles
(high risk) compared favorably to conventional
markers of clinical decision making, using the pres-
ence of LGE (LGEpresence) and LVEF <35% for classi-
fying subjects as high risk of poor outcome and HF
event (Tables 3 and 4, Figures 2 and 3). Combination of
LVEF <35% or LGE with native T1 did not improve
predictive value, indicating the independent patho-
physiological role of diffuse myocardial disease (4).
DISCUSSION
We demonstrate that noninvasive measures of diffuse
myocardial disease by T1 mapping measurements
based on this speciﬁc T1 mapping sequence, are
signiﬁcantly predictive of all-cause mortality and a
composite HF endpoint of HF death and HF hospi-
talization in NIDCM. The predictive associations are
independent of conventional markers of function,
structure, and regional myocardial disease by LGE,
supporting the prominent and independent patho-
physiological role of diffuse myocardial disease in
NIDCM. In multivariate analyses, native T1 measure-
ment was the sole independent predictor of all-cause
mortality and the composite HF endpoint. Our ﬁnd-
ings using this speciﬁc T1 mapping sequence provide
a basis for a novel algorithm of clinical assessment
and risk stratiﬁcation of patients with NIDCM with a
central role for native T1.
To the best of our knowledge this is the ﬁrst report
on the outcome associations with T1 mapping pa-
rameters in NIDCM in a large and multicenter cohort
study, providing insight into the predictive relation-
ships of markers of diffuse myocardial disease by T1
mapping and comparisons with standards of clinical
decision making (25,26). Our results corroborate the
TABLE 3 Results of Univariable and Multivariable Analyses in Prediction of the Outcome
Endpoints for All-Cause Mortality (n ¼ 28, 4.4%)
LR Chi Square
(p Value) Wald
Unadjusted
HR (95% CI)
Signiﬁcant
(p Value)
Univariable analysis
T1 mapping indices
(diffuse disease)
Native T1 (septal)
(per 10ms change)
20.1 (<0.001) 21.3 1.1 (1.06–1.15) <0.001
1.5 T (n ¼ 357) 18.3 (<0.001) 16.8 1.1 (1.09–1.28) <0.001
3.0 T (n ¼ 280) 17.4 (<0.001) 15.8 1.1 (1.08–1.21) <0.001
Native T1 (SAX)
(per 10 ms change)
16.1 (<0.001) 16.0 1.1 (1.04–1.27) <0.001
Post-contrast T1
(per 10 ms change)
5.2 (0.12) 3.2 0.98 (0.97–1.01) 0.53
ECV (per % change) 14.5 (<0.001) 13.4 1.1 (1.05–1.14) <0.001
LGE (regional disease)
LGE (absent/present) 9.2 (0.002) 8.3 2.9 (1.4–6.3) 0.004
LGE extent (per % change) 16.9 (<0.001) 15.7 1.1 (1.05–1.16) <0.001
Myocardial function and structure
EDV (index), ml/m2 5.9 (0.02) 5.7 1.01 (1.0–1.02) 0.016
EF, % 5.7 (0.03) 3.4 0.97 (0.94–0.99) 0.022
LV mass (index), g/m2 5.4 (0.02) 5.2 1.01 (1.0–1.01) 0.024
RVEF, % 8.1 (0.004) 8.1 0.96 (0.93–0.99) 0.005
NYHA functional class (I–II vs. III–IV) 4.0 (0.45) 3.9 2.1 (1.0–4.4) 0.05
MAGGIC score 3.5 (0.069) 3.1 1.04 (1.0–1.12) 0.12
Multivariable analysis
Continuous variables
Model 1* 26.7 (<0.001)
Native T1 (septal)
(per 10 ms change)
24.4 1.1 (1.07–1.17) <0.001
Model 2† 38.1 (<0.001)
Native T1 (septal)
(per 10 ms change)
17.7 1.1 (1.05–1.13) <0.001
LGE extent (per % change) 6.8 1.09 (1.02–1.16) 0.009
Categorical
variables
Native T1 (septal)2SD‡ 23.5 (<0.001) 13.0 5.4 (2.5–15.2) 0.001
Native T1 (septal)tertiles§ 35.2 (<0.001) 22.6 10.5 (3.8–19.2) <0.001
Univariable analyses results are presented with unadjusted hazard ratios (HR) with 95% conﬁdence intervals (CI).
Multivariable analyses were performed with a forward selection (likelihood ratio [LR]) of variables and the
adjusted HR (95% CI) using the variables outlined in bold. We report up to 2 consecutive signiﬁcant models, as
well as the p values for the variables that eventually did not contribute to the model. Accounting for the
interdependency of measures, we avoided multicollinearity by “the strongest of the group” approach. MAGGIC
integer risk score of survival in heart failure is as previously described (19). *Variables not in the model: right
ventricular ejection fraction (RVEF), p ¼ 0.058; late gadolinium enhancement (LGE) extent, p ¼ 0.009; New
York Heart Association (NYHA) functional class (I–II vs. III–IV), p ¼ 0.34. †Variables not in the model: RVEF,
p ¼ 0.19. ‡Variables not in the model: LVEF<35%, p ¼ 0.88; LGE, p¼ 0.12; NYHA functional class (I–II vs. III–IV),
p ¼ 0.64. §Variables not in the model: LVEF <35%, p ¼ 0.61; LGE, p ¼ 0.22; NYHA functional class (I–II vs.
III–IV), p ¼ 0.71.
ECV ¼ extracellular volume fraction; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; HF ¼ heart failure;
LV ¼ left ventricular; LV ¼ left ventricular.
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45predictive association of LGE with survival and HF,
reported previously in NIDCM (7,8). The presence of
any LGE was associated with all-cause mortality and
HF endpoints; notably, midwall striae were the
prevalent LGE pattern observed in our cohort. The
stronger associations for the LGE extent compared to
the presence alone reiterate the utility of this marker
in improving risk stratiﬁcation within the LGE group,
as also shown previously (7,8).
Native T1 and ECV among T1 mapping indices were
both strongly associated with the endpoints, sub-
stantiating their direct relationship to diffuse
myocardial disease as the driver of poor outcome,
independent of regional myocardial disease visualized
by LGE. The differences in performance of T1 indices
largely relate to the choice of sequence and the imag-
ing parameters; the type of a modiﬁed Look-Locker
imaging sequence used in this study is not optimized
to accurately determine the true T1 signal. Because it
is inﬂuenced by T2 decay, it is more sensitive to ab-
normalities in the water-rich myocardial milieu,
explaining the greater effect detected by native T1
compared to post-contrast T1 (27,28). The difﬁculty in
obtaining contemporaneous blood measurement for
hematocrit, as well as different gadolinium doses to
accommodate for patients with reduced estimated
glomerular ﬁltration rate, may be compromising the
accuracy of our ECV results, however, the predictive
associations for ECV are similar to those previously
reported (on a basis of % of change) (29), supporting
the viability of this complex marker in a real-life
clinical scenario (further discussion in the Online
Appendix). Results of ECV (based on this T1 mapping
sequence) mainly rely on native T1 as the driver and
to a lesser extent on the post-contrast T1 measure-
ments resulting in a close interrelatedness of native
T1 and ECV. Whereas the inclusion of larger volumes
of myocardium into the T1 measurements seems
more intuitive, septal measurements compared to
full SAX sampling afford a higher precision as well
as reduce the inclusion of degraded signal due to
noise in the lateral segments diluting the relevant
information (21,30).
Our ﬁndings may help to overcome an important
gap in clinical management and discovery of thera-
pies in NIDCM, and provide a basis for prospective
studies of improved clinical pathways guided by T1
mapping. Native T1—based on this speciﬁc T1
sequence—provides a simple measurement in a single
short and highly reproducible acquisition. Combined
with rapid septal sampling this method offers a robust
and simple standard for clinical routine, capturing the
effects of conditions affecting myocardium diffusely,
as providing a quantiﬁable marker whose magnitudedirectly relates to prognosis (Figures 2 and 3B). In
contrast, LGE reﬂects (extracellular) myocardial dis-
ease, which is visualized once it is sufﬁciently
regionalized, to afford a contrast relative to the non-
enhanced reference (5). By way of an immediate
clinical utility, native T1 is able to inform on the
presence of abnormal myocardium (native T1 >2 SD
above the mean of the normal range), and to detect
TABLE 4 Results of Univariable and Multivariable Analyses in Prediction of the Outcome
Endpoints for a Composite HF Endpoint (n ¼ 68, 10.7%)
LR Chi Square
(p Value) Wald
Unadjusted
HR (95%CI)
Signiﬁcant
(p Value)
Univariable analysis
T1 mapping indices (diffuse disease)
Native T1 (septal)
(per 10 ms change)
24.8 (<0.001) 23.3 1.1 (1.01–1.10) <0.001
1.5-T (n ¼ 357) 22.4 (<0.001) 22.6 1.1 (1.05–1.16) <0.001
3.0-T (n ¼ 280) 23.1 (<0.001) 23.0 1.1 (1.08–1.16) <0.001
Native (SAX) (per 10 ms change) 18.2 (<0.001) 13.7 1.1 (1.0–1.18) <0.001
Post-contrast T1
(per 10 ms change)
5.6 (0.02) 5.2 0.98 (0.96–0.99) 0.023
ECV (per % change) 16.5 (<0.001) 13.8 1.05 (1.02–1.08) 0.004
LGE (regional disease)
LGE (absent/present) 18.5 (<0.001) 16.4 2.7 (1.7–4.3) <0.001
LGE extent (per % change) 11.9 (0.001) 11.3 1.07 (1.03–1.11) 0.001
Myocardial function and structure
EF, % 21.9 (<0.001) 21.2 0.96 (0.94–0.98) <0.001
EDV (index), ml/m2 18.9 (<0.001) 19.5 1.01 (1.007–1.016) <0.001
LV mass (index), g/m2 6.1 (0.014) 6.0 1.004 (1.001–1.01) 0.019
RVEF, % 22.3 (<0.001) 22.2 0.95 (0.94–0.98) <0.001
NYHA functional class (I–II vs. III–IV) 15.4 (<0.01) 12.7 3.2 (2.0–5.2) <0.001
MAGGIC score 14.6 (<0.01) 11.2 1.060 (1.0–1.12) 0.001
Multivariable analysis
Continuous variables
Model 1* 20.9 (<0.001)
Native T1 (septal)
(per 10 ms change)
19.7 1.07 (1.05–1.10) <0.001
Model 2† 27.5 (<0.001)
Native T1 (septal)
(per 10 ms change)
17.2 1.07 (1.04–1.10) <0.001
RVEF, % 11.6 0.94 (0.91–0.98) <0.001
Categorical variables
Native T1 (septal)2SD‡ 30.1 (<0.001) 28.4 4.8 (2.6–9.1) <0.001
Native T1 (septal)tertiles§ 43.9 (<0.001) 42.7 4.7 (2.8–8.0) <0.001
Univariable analyses results are presented with unadjusted HR with 95% CI. Multivariable analyses were per-
formed with a forward selection (LR) of variables and the adjusted HR (95% CI) using the variables outlined in
bold. We report up to 2 consecutive signiﬁcant models, as well as the p values for the variables that eventually
did not contribute to the model. Accounting for the interdependency of measures, we avoided multicollinearity
by “the strongest of the group” approach. MAGGIC integer risk score of survival in heart failure is as previously
described (19). *Variables not in the model: RVEF, p <0.001; LGE (absent/present), p ¼ 0.02; NYHA (I–II vs. III–
IV), p ¼ 0.001. †Variables not in the model: LGE, p ¼ 0.013; NYHA functional class (I–II vs. III–IV), p ¼ 0.007.
‡Variables not in the model: LVEF <35%, p ¼ 0.004; LGE (absent/present), p ¼ 0.02; NYHA functional class (I–II
vs. III–IV), p ¼ 0.001 (16). §Variables not in the model: LVEF <35%, p ¼ 0.013; LGE, p ¼ 0.06; NYHA functional
class (I–II vs. III–IV), p ¼ 0.002.
Abbreviations as in Table 3.
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46those subjects where events are expected with a
greater likelihood (native T1 in the upper tertile or >4
SD above the mean of the normal range), prior to
signiﬁcant functional impairment (EF <35%) and
irrespective of the presence of LGE. Similarly, the low
likelihood of events in those with normal test pro-
vides reassurance by exclusion of relevant myocar-
dial disease. Native T1 (based on this T1 mapping
method) may assume a central role in clinical man-
agement pathway of patients with suspected or
known NIDCM.The performance of T1 mapping indices relates to
their ability to closely approximate the complex
underlying pathophysiology in NIDCM. Due to the
nonspeciﬁc drivers of a change in the T1 imaging
signal, and the plethora of the pathophysiological
mechanisms underlying the myocardial impairment
in NIDCM, eventually culminating into diffuse inter-
stitial ﬁbrosis (1–5), the direct inference to the un-
derlying histological substrate is not absolute. We
and others have previously shown the relevance of T1
mapping in detection of subclinical disease (31–33)
and sensitivity to myocardial inﬂammation (34).
Thus, native T1 and LGE act as independent yet
complementary imaging measures, informing on
important distinction between diffuse and regional
myocardial disease.
As for any diagnostic test, standardization of data
acquisition and post-processing, as well as predeﬁned
reference ranges, are prerequisite for application of
quantiﬁable imaging biomarkers in clinical routine
(35). We achieved this by using a single-vendor plat-
form, unifying the imaging parameters, using iden-
tical contrast type at all sites, performing quality
control of the acquired data, and employing central-
ized post-processing. We beneﬁted from the previ-
ously deﬁned reference ranges (16), utilized the
concept of SD for (ﬁeld-strength independent) clas-
siﬁcation into normal/abnormal and ranking of dis-
ease expression, and deﬁned a group at higher risk
using the upper tertile. This allowed us to identify,
ﬁrstly the presence of (prognostically) relevant dis-
ease, secondly, subjects at high risk of adverse
outcome, and thirdly, to draw comparisons against
standard means of disease detection and risk strati-
ﬁcation (25,26). Baseline characteristics, including
age, sex, NYHA functional class and EF, and conse-
quently MAGGIC score, were less powerful in pre-
dicting survival; however, their relationship with the
HF endpoint persisted in this study, providing an
independent validation of the score in a NIDCM
population. Yet, predictive associations of T1 map-
ping indices were notably stronger compared to LGE
for the HF endpoint, lending support to the premise
that unlike ﬁxed, irreversible injury (seen by LGE),
the activity of diffuse disease (detected by T1 map-
ping) portraits the compensatory capacity within the
remaining viable myocardium.
STUDY LIMITATIONS. A few limitations apply (details
in the Online Appendix). Loss to follow-up is a major
limitation of prognostic studies, including the present
study: upon review the subjects lost were similar to
the overall cohort in terms of heart risk score
(MAGGIC) and T1 mapping indices and, therefore, it is
FIGURE 2 Kaplan-Meier Curves for CMR Parameters and All-Cause Mortality
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(A) Native T1 (normal vs. abnormal myocardium, based on >2 standard deviations [SD] above the mean of the normal reference range) (17), (B) native T1 ranked by
2n-times SD (ranks of SD: <2, $2 to 4, $4 to 6, $6) (17), (C) late gadolinium enhancement present versus absent, and (D) left ventricular ejection fraction <35%.
CMR ¼ cardiac magnetic resonance.
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47unlikely we missed a signiﬁcant number of events.
Imaging was conducted on clinical CMR scanners
with limited research funding, thus contempora-
neous blood measurement for hematocrit could not
be performed. We took care to record the value of
hematocrit as near to the CMR scan as possible, as
well as to avoid any major change of overall health
status or treatment in the interval between blood
sampling to CMR. We believe that our results are a
very close reﬂection of a clinical reality and suggest a
pathway for clinical viability of ECV (further discus-
sion in the Online Appendix). The low overall rate of
events may be explained by the guideline-basedtherapy, the lesser representation of advanced dis-
ease due to implantable devices, and the relatively
short follow-up time. Post hoc power analyses of our
results suggest that it was adequately powered (On-
line Appendix). For wider translation of our ﬁndings,
an external cohort validation based using the same
imaging method, as well as a multivendor cross-
reference is required.
CONCLUSIONS
In summary, noninvasive measures of diffuse
myocardial disease by T1 mapping are signiﬁcantly
FIGURE 3 Kaplan-Meier Curves for CMR Parameters and HF Endpoint
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48predictive of all-cause mortality and HF events in
NIDCM. Our ﬁndings provide a basis for a novel al-
gorithm of clinical assessment and risk stratiﬁcation
of patients with NIDCM—based on this sequence, with
a central role for native T1.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In this
observational longitudinal multicenter study in patients
with NIDCM, noninvasive measures of diffuse myocardial
disease by T1 mapping are able to identify patients at risk
of all-cause mortality as well as heart failure. Using this
particular T1 mapping methodology, native T1 is the
strongest as well as independent predictor. Our ﬁndings
provide a basis for a novel algorithm of clinical assess-
ment and risk stratiﬁcation of patients with NIDCM with a
central role for native T1.
TRANSLATIONAL OUTLOOK: Successful clinical
translation of T1 mapping by CMR may represent one of
the most important advances in clinical management of
NIDCM, allowing noninvasive detection of myocardial
impairment and treatment discovery. For wider transla-
tion of our ﬁndings, an external cohort validation using
the same imaging method, as well as a multivendor cross-
reference is required.
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